Health Care • Medical/Dental Instruments
$2.44 ▲ +0.02
(+0.83%)
MKT CAP: $491.7M • VOL: 1.35M
52W L $1 52W H $3
CERS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $233.8M | $201.3M | $186.8M |
| YoY Revenue Growth % | +16.1% | +7.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$8.7M | -$14.2M | -$30.1M |
| Operating Margin % | -3.7% | -7.1% | -16.1% |
| Net Income (GAAP) | -$15.6M | -$20.9M | -$37.5M |
| EBITDA (Normalized) | -$5.7M | -$12.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $4.8M | $11.4M | -$43.2M |
| Capital Expenditures (CapEx) | $3.7M | $2.8M | — |
| Free Cash Flow (FCF) | $1.1M | $8.5M | -$43.2M |
| FCF Margin % | 0.5% | 4.2% | -23.1% |
| Return on Invested Capital (ROIC %) | -15.5% | -31.3% | — |
| Cash & Short-Term Equivalents | $20.0M | $20.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $64.2M | $56.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CERS.